"CytomX today announced that due to a recent program and portfolio prioritization, the company has decided to indefinitely postpone the clinical trials of CX-188, a PD-1 Probody. The Company may elect to initiate clinical trials of CX-188 in the future.
Bristol-Myers Squibb (BMS) Collaboration Update
As part of our strategic oncology collaboration, BMS has advanced BMS-986249, a CTLA-4 Probody therapeutic, into an ongoing Phase 1/2 clinical trial. BMS has stated that they anticipate preliminary data from this trial in 2019.
In January 2019, BMS provided CytomX notification of termination for three collaboration discovery targets due to portfolio reprioritization. The termination of these targets does not affect other ongoing collaboration discovery and development activities that include BMS-986249."
|aus der Diskussion:||CytomX - ein bahnbrechender Ansatz in der Tumortherapie|
|Autor (Datum des Eintrages):||Aurum2010 (26.02.19 16:35:01)|
|Beitrag:||1,024 von 1,132 (ID:59967928)|
|Alle Angaben ohne Gewähr © wallstreet:online|